131 related articles for article (PubMed ID: 16832818)
21. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice.
Kehrer JP; Margolin SB
Toxicol Lett; 1997 Feb; 90(2-3):125-32. PubMed ID: 9067480
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effect of Chinese medicine formula DSQRL on experimental pulmonary fibrosis.
Zhang HQ; Yau YF; Szeto KY; Chan WT; Wong J; Li M
J Ethnopharmacol; 2007 Feb; 109(3):543-6. PubMed ID: 16987627
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effects of alpha-lipoic acid on bleomycin-induced pulmonary fibrosis in rats.
Liu R; Ahmed KM; Nantajit D; Rosenthal FS; Hai CX; Li JJ
Int J Mol Med; 2007 Jun; 19(6):865-73. PubMed ID: 17487418
[TBL] [Abstract][Full Text] [Related]
24. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.
Gosselin LE; Williams JE; Personius K; Farkas GA
Muscle Nerve; 2007 Feb; 35(2):208-16. PubMed ID: 17058274
[TBL] [Abstract][Full Text] [Related]
25. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
Levitt J; Gould MK
Am J Respir Crit Care Med; 2005 Nov; 172(9):1228-9; author reply 1229. PubMed ID: 16249322
[No Abstract] [Full Text] [Related]
26. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.
Furonaka M; Hattori N; Tanimoto T; Senoo T; Ishikawa N; Fujitaka K; Haruta Y; Yokoyama A; Kohno N
J Pharmacol Exp Ther; 2009 Jan; 328(1):55-61. PubMed ID: 18832650
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Chowdhury MA; Abdellatif KR; Dong Y; Das D; Suresh MR; Knaus EE
Bioorg Med Chem Lett; 2008 Dec; 18(23):6138-41. PubMed ID: 18945614
[TBL] [Abstract][Full Text] [Related]
28. Potent antioxidant role of pirfenidone in experimental cirrhosis.
Salazar-Montes A; Ruiz-Corro L; López-Reyes A; Castrejón-Gómez E; Armendáriz-Borunda J
Eur J Pharmacol; 2008 Oct; 595(1-3):69-77. PubMed ID: 18652820
[TBL] [Abstract][Full Text] [Related]
29. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.
Nakayama S; Mukae H; Sakamoto N; Kakugawa T; Yoshioka S; Soda H; Oku H; Urata Y; Kondo T; Kubota H; Nagata K; Kohno S
Life Sci; 2008 Jan; 82(3-4):210-7. PubMed ID: 18093617
[TBL] [Abstract][Full Text] [Related]
30. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
Azuma A
Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
[TBL] [Abstract][Full Text] [Related]
31. Forsterite exposure causes less oxidative DNA damage and lung injury than chrysotile exposure in rats.
Takata A; Yamauchi H; Toya T; Aminaka M; Shinohara Y; Kohyama N; Yoshida K
Inhal Toxicol; 2009 Aug; 21(9):739-46. PubMed ID: 19645569
[TBL] [Abstract][Full Text] [Related]
32. [Idiopathic pulmonary fibrosis -- progress in sight].
Kaarteenaho R; Hodgson U; Myllärniemi M
Duodecim; 2011; 127(24):2639-45. PubMed ID: 22320106
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin.
Cabrera S; Gaxiola M; Arreola JL; Ramírez R; Jara P; D'Armiento J; Richards T; Selman M; Pardo A
Int J Biochem Cell Biol; 2007; 39(12):2324-38. PubMed ID: 17702637
[TBL] [Abstract][Full Text] [Related]
34. Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat.
Rasooli R; Rajaian H; Pardakhty A; Mandegary A
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):25-32. PubMed ID: 28696894
[TBL] [Abstract][Full Text] [Related]
35. [Effects of cordyceps sinensi on bleomycin-induced pulmonary fibrosis in mice].
Wang SJ; Bai W; Wang CL; Dai Z
Zhongguo Zhong Yao Za Zhi; 2007 Dec; 32(24):2623-7. PubMed ID: 18338602
[TBL] [Abstract][Full Text] [Related]
36. Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?
Onoue S; Yamada S
Ther Deliv; 2013 Aug; 4(8):887-9. PubMed ID: 23919466
[No Abstract] [Full Text] [Related]
37. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.
Izumo T; Kondo M; Nagai A
Life Sci; 2007 Apr; 80(20):1882-6. PubMed ID: 17397875
[TBL] [Abstract][Full Text] [Related]
38. Optimal treatment for idiopathic pulmonary fibrosis.
Maher TM; Wells AU
Thorax; 2008 Dec; 63(12):1120-1; author reply 1121. PubMed ID: 19020278
[No Abstract] [Full Text] [Related]
39. Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats.
Ghazi-Khansari M; Mohammadi-Karakani A; Sotoudeh M; Mokhtary P; Pour-Esmaeil E; Maghsoud S
J Appl Toxicol; 2007; 27(4):342-9. PubMed ID: 17265423
[TBL] [Abstract][Full Text] [Related]
40. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers.
Shi S; Wu J; Chen H; Chen H; Wu J; Zeng F
J Clin Pharmacol; 2007 Oct; 47(10):1268-76. PubMed ID: 17906160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
